Innoviva Price to Free Cash Flow Ratio 2012-2026 | INVA
Historical price to free cash flow ratio values for Innoviva (INVA) since 2012.
| Innoviva Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-06-15 | 22.42 | 13.48 | |
| 2026-03-31 | 23.30 | $1.66 | 14.01 |
| 2025-09-30 | 18.25 | $2.15 | 8.49 |
| 2025-06-30 | 20.09 | $2.35 | 8.57 |
| 2025-03-31 | 18.13 | $2.88 | 6.30 |
| 2024-12-31 | 17.35 | $2.54 | 6.83 |
| 2024-09-30 | 19.31 | $2.42 | 7.96 |
| 2024-06-30 | 16.40 | $1.94 | 8.46 |
| 2024-03-31 | 15.24 | $1.77 | 8.60 |
| 2023-12-31 | 16.04 | $1.62 | 9.91 |
| 2023-09-30 | 12.99 | $1.35 | 9.60 |
| 2023-06-30 | 12.73 | $1.24 | 10.26 |
| 2023-03-31 | 11.25 | $1.36 | 8.29 |
| 2022-12-31 | 13.25 | $2.12 | 6.26 |
| 2022-09-30 | 11.61 | $2.62 | 4.43 |
| 2022-06-30 | 14.76 | $4.03 | 3.66 |
| 2022-03-31 | 19.35 | $4.16 | 4.65 |
| 2021-12-31 | 17.25 | $3.86 | 4.47 |
| 2021-09-30 | 16.71 | $4.00 | 4.18 |
| 2021-06-30 | 13.41 | $3.08 | 4.35 |
| 2021-03-31 | 11.95 | $2.85 | 4.19 |
| 2020-12-31 | 12.39 | $2.76 | 4.49 |
| 2020-09-30 | 10.45 | $2.60 | 4.03 |
| 2020-06-30 | 13.98 | $2.45 | 5.72 |
| 2020-03-31 | 11.76 | $2.24 | 5.25 |
| 2019-12-31 | 14.16 | $2.27 | 6.24 |
| 2019-09-30 | 10.54 | $2.22 | 4.74 |
| 2019-06-30 | 14.56 | $2.25 | 6.47 |
| 2019-03-31 | 14.03 | $2.21 | 6.36 |
| 2018-12-31 | 17.45 | $1.97 | 8.85 |
| 2018-09-30 | 15.24 | $1.83 | 8.35 |
| 2018-06-30 | 13.80 | $1.66 | 8.31 |
| 2018-03-31 | 16.67 | $1.39 | 11.98 |
| 2017-12-31 | 14.19 | $1.18 | 12.00 |
| 2017-09-30 | 14.12 | $0.95 | 14.84 |
| 2017-06-30 | 12.80 | $0.75 | 17.01 |
| 2017-03-31 | 13.83 | $0.66 | 20.98 |
| 2016-12-31 | 10.70 | $0.49 | 21.72 |
| 2016-09-30 | 10.99 | $0.39 | 28.54 |
| 2016-06-30 | 10.53 | $0.24 | 43.60 |
| 2016-03-31 | 12.59 | $0.17 | 75.84 |
| 2015-12-31 | 10.54 | $0.09 | 120.05 |
| 2015-09-30 | 7.18 | $-1.23 | 0.00 |
| 2015-06-30 | 17.74 | $-1.42 | 0.00 |
| 2015-03-31 | 15.21 | $-1.42 | 0.00 |
| 2014-12-31 | 13.52 | $-2.38 | 0.00 |
| 2014-09-30 | 16.04 | $-2.38 | 0.00 |
| 2014-06-30 | 27.65 | $-2.56 | 0.00 |
| 2014-03-31 | 23.15 | $-2.76 | 0.00 |
| 2013-12-31 | 26.67 | $-2.12 | 0.00 |
| 2013-09-30 | 30.57 | $-1.11 | 0.00 |
| 2013-06-30 | 28.82 | $-1.00 | 0.00 |
| 2013-03-31 | 17.67 | $-1.23 | 0.00 |
| 2012-12-31 | 16.64 | $-1.36 | 0.00 |
| 2012-09-30 | 19.38 | $-1.44 | 0.00 |
| 2012-06-30 | 16.62 | $-1.42 | 0.00 |
| 2012-03-31 | 14.59 | $-1.24 | 0.00 |
| 2011-12-31 | 16.53 | $-1.12 | 0.00 |
| 2011-09-30 | 15.07 | $-1.03 | 0.00 |
| 2011-06-30 | 16.61 | $-1.06 | 0.00 |
| 2011-03-31 | 18.12 | $-1.03 | 0.00 |
| 2010-12-31 | 18.75 | $-1.05 | 0.00 |
| 2010-09-30 | 15.04 | $-0.86 | 0.00 |
| 2010-06-30 | 9.40 | $-0.96 | 0.00 |
| 2010-03-31 | 9.96 | $-0.87 | 0.00 |
| 2009-12-31 | 9.78 | $-0.93 | 0.00 |
| 2009-09-30 | 10.95 | $-1.22 | 0.00 |
| 2009-06-30 | 10.95 | $-1.12 | 0.00 |
| 2009-03-31 | 12.72 | $-1.46 | 0.00 |
| 2008-12-31 | 9.27 | $-1.64 | 0.00 |
| 2008-09-30 | 9.32 | $-1.95 | 0.00 |
| 2008-06-30 | 8.88 | $-1.90 | 0.00 |
| 2008-03-31 | 7.88 | $-2.20 | 0.00 |
| 2007-12-31 | 14.59 | $-1.89 | 0.00 |
| 2007-09-30 | 19.52 | $-1.82 | 0.00 |
| 2007-06-30 | 23.94 | $-2.08 | 0.00 |
| 2007-03-31 | 22.07 | $-1.42 | 0.00 |
| 2006-12-31 | 23.11 | $-1.87 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |